Virtus ETF Advisers’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Virtus ETF Advisers’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,536	Closed	-$290K	–	405
2021 Q2	$290K	Sell	10,536 -624	-6%	-$12.3K	0.12%	201
2021 Q1	$184K	Buy	11,160 +201	+2%	+$4.58K	0.08%	336
2020 Q4	$202K	Sell	10,959 -9,640	-47%	-$173K	0.08%	345
2020 Q3	$280K	Sell	20,599 -2,796	-12%	-$43.1K	0.15%	239
2020 Q2	$419K	Sell	23,395 -18,217	-44%	-$275K	0.2%	184
2020 Q1	$415K	Sell	41,612 -6,073	-13%	-$49.8K	0.17%	193
2019 Q4	$388K	Buy	+47,685	New	+$440K	0.06%	269

Virtus ETF Advisers's TBIO Position: Q3 2021 in Review

Virtus ETF Advisers sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 10,536 shares — an estimated $290K sold.

Virtus ETF Advisers first reported a position in TBIO in Q4 2019 and held it in 7 quarters. The position peaked at $419K in Q2 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

Virtus ETF Advisers reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Virtus ETF Advisers sold 10,536 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $290K.
Virtus ETF Advisers first reported a position in Translate Bio, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
Virtus ETF Advisers's Translate Bio, Inc. Common Stock position peaked at $419K in Q2 2020.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Virtus ETF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.